急性SARS-CoV-2感染婴儿高心肌肌钙蛋白水平的前瞻性对照研究
这项前瞻性多中心三臂对照研究纳入152例因COVID-19住院的婴儿、79例其他急性感染儿童和71例健康对照,发现COVID-19组高敏心肌肌钙蛋白(hs-cTn)超过正常上限和升高3倍的比例均显著高于两个对照组,且升高与年龄<3个月相关,随访至1年所有患儿hs-cTn逐渐正常化且无心脏临床表现。
要点
- COVID-19婴儿hs-cTn超过正常上限比例28.9%,升高3倍比例13.2%,均显著高于对照组。
- SARS-CoV-2感染患儿hs-cTn升高3倍的风险显著高于健康儿童(OR 5.23)和其他感染儿童(OR 11.89)。
- hs-cTn升高与年龄<3个月相关(P < .001),随访至1年逐渐正常化且无心脏功能损害表现。
核心结论
- 急性SARS-CoV-2感染婴儿可出现亚临床、短暂的心肌损伤标志物升高,尤其在出生后前几个月。
- hs-cTn水平随访期间正常化,未伴随心脏功能损害,但长期后果未知需仔细随访。
研究设计与样本
- 前瞻性、多中心、三臂对照研究,2020年3月至2022年3月纳入152例因COVID-19住院婴儿、79例其他急性感染儿童和71例健康对照。
- 主要结局为测定高敏心肌肌钙蛋白(hs-cTn)水平。
主要发现
- COVID-19组hs-cTn超过正常上限的比例为28.9%(44例),升高3倍的比例为13.2%(20例),均显著高于两个对照组。
- SARS-CoV-2感染患儿hs-cTn升高3倍的风险高于健康儿童(OR 5.23;95% CI 1.19-23.02)和其他感染儿童(OR 11.89;95% CI 1.56-89.79)。
- COVID-19患儿hs-cTn升高与临床、生化特征及围产期危险因素无关,但与年龄<3个月相关(P < .001)。
- 调整年龄、性别和基础临床状况后,多变量回归模型显示hs-cTn升高与COVID-19独立相关。
- 所有患儿随访至1年hs-cTn逐渐降至正常,无临床、心电图或超声心动图表现。
关键数值与推荐
- hs-cTn超过正常上限:COVID-19组44例(28.9%),显著高于对照组。
- hs-cTn升高3倍:COVID-19组20例(13.2%),显著高于对照组。
- hs-cTn升高3倍风险:vs健康儿童OR 5.23(95% CI 1.19-23.02),vs其他感染儿童OR 11.89(95% CI 1.56-89.79)。
- 年龄<3个月与COVID-19患儿hs-cTn升高相关(P < .001)。
临床怎么用
- 对于急性SARS-CoV-2感染的婴儿,尤其年龄<3个月者,可考虑监测hs-cTn以识别亚临床心肌损伤。
- hs-cTn升高通常呈短暂和亚临床过程,随访中可正常化,无心脏功能损害表现,但仍需仔细长期随访。
局限性
- 长期后果未知,需进一步随访研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the specific role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in inducing elevation of marker of myocardial injury in infants with acute coronavirus disease 2019 (COVID-19). STUDY DESIGN: A prospective, multicentric 3-arm comparative study (March 2020 through March 2022) enrolling 152 infants hospitalized for COVID-19, 79 children with acute infections other than SARS-CoV-2, and 71 healthy controls. Determination of high-sensitivity cardiac troponin (hs-cTn) levels was the primary outcome. RESULTS: The proportion of children with hs-cTn values above the upper limit of normal (44 [28.9%]), as well as with a 3-fold increased value (20 [13.2%]) were significantly higher in the COVID-19 group than those in both control groups. The risk of presenting a 3-fold increased hs-cTn value was higher in children with SARS-CoV-2 infection compared with either healthy children (OR, 5.23; 95% CI, 1.19-23.02) or those with other infections (OR, 11.89; 95% CI, 1.56-89.79). In children with COVID-19, hs-cTn elevation was associated with neither clinical nor biochemical characteristics, nor perinatal risk factors, but with an age of <3 months (P < .001). After adjustment for age, sex, and underlying clinical conditions, elevated hs-cTn was independently associated with COVID-19 in a multivariable regression model. All children showed a progressive reduction of hs-cTn until normalization over time, without clinical, ECG, or echocardiographic manifestations up to 1 year of follow-up. CONCLUSIONS: Infants with acute SARS-CoV-2 infection may show a subclinical and transient alteration of myocardial injury markers, especially in the first months of life. hs-cTn levels normalized during follow-up and were not associated with cardiac functional impairment; nevertheless, long-term consequences are unknown and should be followed carefully.
引用
- Lo Vecchio A, Scarano SM, Pierri L, et al. High Cardiac Troponin Levels in Infants with Acute SARS-CoV-2 Infection: A Prospective Comparative Study. J Pediatr. 2023. PMID: 38135032. doi:10.1016/j.jpeds.2023.113876
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。